Synergy between immunosuppressive therapy and enteral nutrition in the management of childhood Crohn's disease

Journal of Parenteral and Enteral Nutrition

Volumn 29, Issue 4_suppl, 2005, Pages S160-S165

  Heuschkel, Robert ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHILD; CHILD NUTRITION; CROHN DISEASE; ENTERIC FEEDING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; PRIORITY JOURNAL; REMISSION; DRUG COMBINATION; DRUG POTENTIATION; REVIEW; TREATMENT OUTCOME;

CHILD; CROHN DISEASE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENTERAL NUTRITION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 27744526242     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/01486071050290S4S160     Document Type: Article

References (30)

1. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther. 2000; 14: 281-289.
2. Ruuska T, Savilahti E, Maki M, et al. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr. 1994; 19: 175-180.
3. Griffiths AM. Enteral nutrition: the neglected primary therapy of active Crohn's disease. J Pediatr Gastroenterol Nutr. 2000; 31: 3-5.
4. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr. 2000; 31: 8-15.
5. Heuschkel RB, MacDonald TT, Monteleone G, et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut. 2000; 47: 57-62.
6. Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut. 1990; 31: 325-328.
7. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12: 439-447.
8. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994; 35: 231-235.
9. Gomes P, du BC, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986; 27: 92-95.
10. Lorenz-Meyer H, Malchow H, Miller B, et al. European Cooperative Crohn's Disease Study (ECCDS): colonoscopy. Digestion. 1985; 31: 109-119.
11. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 1999; 353: 459-461.
12. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22.
13. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18 (Suppl): 1-5.
14. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993; 34: 1081-1085.
15. Fuentes D, Torrente F, Keady S, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 17: 913-921.
16. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997; 112: 1475-1481.
17. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000; 119: 895-902.
18. Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther. 2002; 16: 857-867.
19. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110: 353-356.
20. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000; 342: 1627-1632.
21. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999; 116: 1029-1034.
22. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761-769.
23. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000; 95: 3189-3194.
24. Bannerjee K, Camacho-Hubner C, Babinska K, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr. 2004; 38: 270-275.
25. Afzal NA, Van Der Zaag-Loonen HJ, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004; 20: 167-172.
26. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 + T lymphocytes. J Clin Invest. 2003; 111: 1133-1145.
27. Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005; 312: 537-545.
28. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut. 1996; 38: 543-548.
29. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988; 94: 603-610.
30. Bousvaros A. Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill? Inflamm Bowel Dis. 2004; 10: 481-483.